Abstract 2305
Background
This study aimed to examine the effects of progressive muscle relaxation (PMR) and mindfulness-based stress reduction (MBSR) on fatigue, coping styles and quality of life (QOL) in breast cancer patients receiving adjuvant paclitaxel regimen.
Methods
Participants (stages 1-3) were randomly assigned to either a 12-week (PMR) (n = 31), MBSR (n = 32) interventions or control group (CG) (n = 29). Participants in the intervention groups were instructed on PMR and MBSR, the steps of interventions were recorded a voice recorder, and were asked to listen the recorded audio files during exercises. Participants in the intervention groups continued PMR or MBSR 20 min. each day, totally 12 weeks at their home. The CG received only a single time attention placebo education (15 min.) on breast cancer before paclitaxel regimen. No intervention was applied to neither the interventions nor the control group until the follow-up assessment (week 14). Data collection tools included Patient Information Form, Brief Fatigue Inventory (BFI), Brief COPE, and the Functional Living Index-Cancer (FLIC). The data were collected at three time points including at baseline, week 12, and week 14. To analyze data repeated measures ANOVA and Kruskal Wallis tests were used.
Results
The BFI scores were significantly decreased in the MBSR, PMR groups when compared with the CG at week 12 and week 14 (p<.05). The use of emotional support, use of instrumental support, venting, positive reframing, and planning sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 12 and week 14 (p<.05). Besides, the humor and acceptance sub-dimension scores of Brief COPE were significantly higher in the MBSR, and PMR groups than the CG at week 14 (p<.05). Regarding FLIC, QOL scores, there were no significant differences between the groups at week 12 and week 14 (p>.05).
Conclusions
A brief, PMR and MBSR are simple and effective nursing interventions, initiated concurrently with adjuvant paclitaxel regimen that can be used to manage fatigue, and improve coping styles in patients with breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University, Scientific Research Projects Coordination Unit (project THD-2018-17089).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract